Tags : Nadia Tarolli

Corporate Pharma

Vischer advises Oculis on its public listing on Nasdaq

Oculis Holding, a global biopharmaceutical company, purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”). At closing, Oculis had a pro-forma enterprise value of approximately USD 220m and a cash balance exceeding USD 117m prior to payment of […]

Deal & transactions

VISCHER advises Novaremed on its agreement with NeuroFront

Novaremed, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for non-opioid investigational drug, NRD.E1. The Novaremed’s innovative non-opioid drug is being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications. Under the […]

Banking & Finance

Anaveon to raise CHF 110 million in Series B Financing.

Anaveon, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax. In connection with […]

Capital Markets

Bachem Holding places shares of approx. CHF 584 m. The

Bachem Holding, an innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides, has raised CHF 583.5 million through an accelerated bookbuilding process by issuing 750,000 new shares at a placement price of CHF 778 per share.  Mor­gan Stan­ley and UBS were act­ing as Joint Glob­al Coordin­at­ors and Joint Book­run­ners and Zürch­er Kan­ton­al­bank as Joint […]

Deal & transactions

Vischer advises Novaremed in its acquisition of Metys Pharmaceuticals

Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals.   The acquisition broadens Novaremed’s existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment.   Vischer advises Novaremed with a […]

Deal & transactions

Polyphor signs merger agreement with EnBiotix. The advisors

EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in exchange for Polyphor Shares was signed.  Polyphor will be renamed and is expected to trade under a new ticker symbol on the Swiss Stock Exchange.  EnBiotix is also acquiring inhaled murepavadin for an agreed value of USD 10 million […]

Deal & transactions

Vischer in the the sale of Mestex AG to Grünenthal

Vischer advised the sellers of Mestex AG on all legal issues related to the sale of their shares and stock options to the pharmaceutical company Grünenthal, a global operator in pain management and related diseases. With the acquisition, Grünenthal aims to grow in the global market for osteoarthritis drugs and further strengthen its pain treatment-focused […]